Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v9-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2020-01-16 | 2019-02-21 |
Drug Identification Number | 02401029 | 02401029 |
Brand name | CEFAZOLIN FOR INJECTION, USP | CEFAZOLIN FOR INJECTION, USP |
Common or Proper name | Cefazolin for Injection, USP | Cefazolin for Injection, USP |
Company Name | FRESENIUS KABI CANADA LTD | FRESENIUS KABI CANADA LTD |
Ingredients | CEFAZOLIN | CEFAZOLIN |
Strength(s) | 100G | 100G |
Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS | INTRAVENOUS |
Packaging size | 100g SmartPak | 100g SmartPak |
ATC code | J01DB | J01DB |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | 2019-11-01 | 2019-02-21 |
Actual start date | ||
Estimated end date | 2019-12-16 | Unknown |
Actual end date | 2020-01-13 | |
Shortage status | Resolved | Anticipated shortage |
Tier 3 Status | No | No |
Company comments | Product Available 25% Allocation effective January 13th, 2020 | Fresenius Kabi Canada Ltd. regrets to advise that due to a production interruption, we will be placing our Cefazolin for Injection, USP 100 g SmartPak® on reduced allocation. Contract customers will be allocated 50% of their historical average monthly volumes. If you have any questions or concerns, please do not hesitate to contact Customer Service at (877) 821-7724. |
Health Canada comments |